

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3518.1015-000APPLICATION NO.
10/630,227INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONFIRST NAMED INVENTOR
Thomas M. DiMauroFILING DATE
July 30, 2003

October 11, 2005

(Use several sheets if necessary)

EXAMINER
Lee, Betty L.CONFIRMATION NO.
8291GROUP
1647

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
gms	A1	2003/0039651 A1	02-27-2003	Olmarker
	A2	6,419,944 B2	07-16-2002	Tobinick
	A3	2003/0049256 A1	03-13-2003	Tobinick
	A4	2002/0026244 A1	02-28-2002	Trieu
	A5	5,095,037	03-10-1992	Iwamitsu <i>et al.</i>
	A6	6,049,026	04-11-2000	Muschler
	A7	5,231,024	07-27-1993	Moeller <i>et al.</i>
	A8	6,284,471 B1	09-04-2001	Le <i>et al.</i>
	A9	5,447,851	09-05-1995	Beutler <i>et al.</i>
	A10	5,116,964	05-26-1992	Capon <i>et al.</i>
	A11	5,225,538	07-06-1993	Capon <i>et al.</i>
	A12	6,277,969 B1	08-21-2001	Le <i>et al.</i>
	A13	6,541,477 B2	04-01-2003	Goehring <i>et al.</i>
	A14	5,965,583	10-12-1999	Beers <i>et al.</i>
	A15	5,728,396	03-17-1998	Peery <i>et al.</i>
	A16	5,270,300	12-14-1993	Hunziker
	A17	6,294,170 B1	09-25-2001	Boone <i>et al.</i>
	A18	2001/0016195 A1	08-23-2001	Tobinick
	A19	5,368,841	11-29-1994	Trauner <i>et al.</i>
	A20	4,427,649	01-24-1984	Dingle <i>et al.</i>
	A21	5,656,272	08-12-1997	Le <i>et al.</i>


EXAMINER

DATE CONSIDERED

12-4-05


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 11, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1015-000		APPLICATION NO. 10/630,227	
	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE July 30, 2003	
	EXAMINER Lee, Betty L.		CONFIRMATION NO. 8291	GROUP 1647

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
CMS	B1	EP 1153607 A2	11-14-2001	Dunn	
	B2	WO 03/000190 A2	01-03-2003	DePuy	
	B3	WO 02/057240 A1	07-25-2002	Ortho Mc Neil Pharmaceutical, Inc.	
	B4	WO 91/02078	02-21-1991	Peptide Technology LTD	
	B5	EP 0 218 868 A2	04-22-1987	New York Blood Center, Inc.	
	B6	EP 0 288 088 B1	10-26-1988	Teijin Limited	
	B7	WO 92/07076	04-30-1992	The Charing Cross Sunley Research Centre	
	B8	WO 2004/022078 A1	03-18-2004	The Royal Veterinary College	
	B9	WO 97/28828	08-14-1997	Amgen Boulder Inc.	
	B10	WO 92/16553	10-01-1992	New York University	
	B11	WO 98/24477	06-11-1998	Amgen Inc.	
	B12	EP 1 133 995 A2	09-19-2001	Synergen, Inc.	
	B13	WO 01/85179 A2	11-15-2001	Clemson University	
	B14	EP 0 438 234 A1	07-24-1991	Kita	




EXAMINER 	DATE CONSIDERED 12-4-05
--	-----------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 11, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1015-000		APPLICATION NO. 10/630,227	
	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE July 30, 2003	
	EXAMINER Lee, Betty L.		CONFIRMATION NO. 8291	GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
(A)	C1	Braun, J. and Sieper J., "Overview of The Use of The Anti-TNF Agent Infliximab in Chronic Inflammatory Diseases," <i>Expert Opin. Biol. Ther.</i> 3(1):141-168 (2003).
	C2	Braun, J., <i>et al.</i> , "Anti-Tumour Necrosis Factor α Therapy for Ankylosing Spondylitis: International Experience," <i>Ann. Rheum. Dis.</i> , 61(Supp. III):iii51-iii60 (2002).
	C3	Olmarker, K. and Rydevik, B., "Selective Inhibition of Tumor Necrosis Factor- α Prevents Nucleus Pulposus-Induced Thrombus Formation, Intraneural Edema, and Reduction of Nerve Conduction Velocity," <i>Spine</i> , 26(8):863-869 (2001).
	C4	Aoki, Y., <i>et al.</i> , "Local Application of Disc-Related Cytokines on Spinal Nerve Roots," <i>Spine</i> 27(15): 1614-1617 (2002).
	C5	Tobinick, E.L. and Britschgi-Davoodifar, S., "Perispinal TNF-Alpha Inhibition for Discogenic Pain," <i>Swiss Med. Weekly</i> , 133:170-77 (2003).
	C6	Maeda, S. and Kokubun, S., "Changes With Age in Proteoglycan Synthesis in Cells Cultured <i>In Vitro</i> From the Inner and Outer Rabbit Annulus Fibrosus," <i>Spine</i> , 25(2):166-169 (2000).
	C7	Igarashi <i>et al.</i> , Inflammatory Cytokines From Facet Joint Tissue in Degenerative Lumbar Disorder, ISSLS Abstract #262 (May 13-17, 2003).
	C8	Wittenberg, <i>et al.</i> , "In Vitro Release of Prostaglandins and Leukotrienes From Synovial Tissue, Cartilage, and Bone in Degenerative Joint Diseases," <i>Arthritis Rheum.</i> , 36(10):1444-1450 (Oct. 1993).
	C9	Kawakami, M. <i>et al.</i> , "Possible Mechanism of Painful Radiculopathy in Lumbar Disc Herniation," <i>Clin. Orthop.</i> 351:241-251(1998).
	C10	Gordon, J.L., <i>et al.</i> , "Metalloproteinase Inhibitors as Therapeutics," <i>Clin. Exp. Rheumatol.</i> , 11(Supp 8): S91-S94 (1993).
	C11	Johnson, W.H., <i>et al.</i> , "Collagenase Inhibitors: Their Design and Potential Therapeutic Use," <i>J. Enzyme Inhib.</i> , 2:1-22 (1987).
	C12	Möller, A. <i>et al.</i> , "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> 2(3):162-169 (1990).


EXAMINER 	DATE CONSIDERED 12-4-05
--	-----------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 11, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227	
	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE July 30, 2003
	EXAMINER Lee, Betty L.	CONFIRMATION NO. 8291	GROUP 1647



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	C13	Liang, C.-M., <i>et al.</i> , "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. Biophys. Res. Comm.</i> 137:847-854 (1986).		
	C14	Meager, A., <i>et al.</i> , "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> 6(3):305-311 (1987).		
	C15	Fendly <i>et al.</i> , "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> 6:359-370 (1987).		
	C16	Bringman, T.S., <i>et al.</i> , "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> 6(5):489-507 (1987).		
	C17	Hirai, M., <i>et al.</i> , "Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor," <i>J. Immunol. Meth.</i> 96:57-62 (1987).		
	C18	Schall, T., <i>et al.</i> , "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).		
	C19	Loetscher, H., <i>et al.</i> , "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).		
	C20	Corcoran, A., <i>et al.</i> , "Characterization of Ligand Binding by the Human p55 Tumour-Necrosis-Factor Receptor," <i>Eur. J. Biochem.</i> , 223:831-840 (1994).		
	C21	Engelmann, H. <i>et al.</i> , "Two Tumor Necrosis Factor-Binding Proteins Purified From Human Urine," <i>J. Biol. Chem.</i> , 265(3):1531-1536 (1990).		
	C22	Lesslauer, W., <i>et al.</i> , "Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice from Lipopolysaccharide-Induced Lethality," <i>Eur. J. Immunol.</i> , 21:2883-2886 (1991).		
	C23	Ashkenazi, A., <i>et al.</i> , "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoconjugate," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-10539 (1991).		
	C24	Peppel, K., <i>et al.</i> , "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> , 174:1483-1489 (1991).		
<table border="1"> <tr> <td data-bbox="110 1923 743 1997"> EXAMINER  </td> <td data-bbox="743 1923 1505 1997"> DATE CONSIDERED 12-4-05 </td> </tr> </table>			EXAMINER 	DATE CONSIDERED 12-4-05
EXAMINER 	DATE CONSIDERED 12-4-05			


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 11, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227	
	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE July 30, 2003
	EXAMINER Lee, Betty L.	CONFIRMATION NO. 8291	GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
CHS	C25	Capon, D., <i>et al.</i> , "Designing CD4 Immunoadhesins for AIDS Therapy," <i>Nature</i> , 337:525-531 (1989).
	C26	Kolls, J., <i>et al.</i> , "Prolonged and Effective Blockade of Tumor Necrosis Factor Activity Through Adenovirus-Mediated Gene Transfer," <i>Proc. Natl. Acad. Sci. USA</i> 91:215-219 (1994).
	C27	Butler, D., <i>et al.</i> , "TNF Receptor Fusion Proteins are Effective Inhibitors of TNF-Mediated Cytotoxicity on Human KYM-1D4 Rhabdomyosarcoma Cells," <i>Cytokine</i> , 6(6):616-623 (1994).
	C28	Baker, D., <i>et al.</i> , "Control of Established Experimental Allergic Encephalomyelitis by Inhibition of Tumor Necrosis Factor (TNF) Activity within the Central Nervous System using Monoclonal Antibodies and TNF Receptor-Immunoglobulin Fusion Proteins," <i>Eur. J. Immunol.</i> , 24:2040-2048 (1994).
	C29	Zhang, C., <i>et al.</i> , "Mitogen-activated Protein (MAP) Kinase Regulates Production of Tumor Necrosis Factor- α and Release of Arachidonic Acid in Mast Cells," <i>J. Biol. Chem.</i> , 272(20): 13397-13402 (1997).
	C30	Pargellis, C., <i>et al.</i> , "Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site," <i>Nature Structural Biology</i> , 9(4): 268-272 (2002).
	C31	Chae, H.J., <i>et al.</i> , "The p38 Mitogen-activated Protein Kinase Pathway Regulates Interleukin-6 Synthesis in Response to Tumor Necrosis Factor in Osteoblasts," <i>Bone</i> , 28(1): 45-53 (2001).
	C32	Cirillo, P., <i>et al.</i> , "The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors," <i>Current Topics in Medicinal Chemistry</i> , 2:1021-1035 (2002).
	C33	Boehm, J. and Adams, J., "New Inhibitors of p38 Kinase," <i>Exp. Opin. Ther. Patents</i> , 10(1):25-38 (2000).
	C34	Lee <i>et al.</i> , "Inhibition of p38 MAP Kinase as a Therapeutic Strategy," <i>Immunopharmacology</i> , 47:185-2001 (2000).
	C35	Brown, K., <i>et al.</i> , "Gelatin/Chondroitin 6-Sulfate Microspheres for the Delivery of Therapeutic Proteins to the Joint," <i>Arthritis. Rheum.</i> , 41(12):2185-2195 (1998).
✓	C36	Burke, J.G., <i>et al.</i> , "Intervertebral Discs Which Cause Low Back Pain Secrete High Levels of Proinflammatory Mediators," <i>JBJS</i> , 84-B(2):196-201 (2002).

EXAMINER 	DATE CONSIDERED 12-4-05
--	-----------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 11, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1015-000		APPLICATION NO. 10/630,227	
	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE July 30, 2003	
	EXAMINER Lee, Betty L.		CONFIRMATION NO. 8291	GROUP 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C37	Gabay, C., "IL-1 Trap," <i>Curr. Opin. Invest. Drugs, Curr. Drugs</i> , London, GB, 4(5):593-597 (2003).
	C38	Dayer, J.M., "The Pivotal Role of Interleukin-1 in the Clinical Manifestations of Rheumatoid Arthritis," <i>Rheumatology, Oxford Univeristy Press</i> , London, GB, 42(Suppl 2):ii03-ii10 (2003).

EXAMINER 	DATE CONSIDERED 12-4-05
--	-----------------------------------